University of Texas MD Anderson Cancer Center
-
Pics News
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
[ad_1] Newswise — SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective…
Read More » -
Health News
ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
[ad_1] Newswise — SAN DIEGO ― The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while…
Read More » -
Health News
ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias
[ad_1] Newswise — Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results…
Read More » -
Health News
MD Anderson and Rigel Pharmaceuticals announce strategic alliance to advance olutasidenib in AML and other cancers
[ad_1] Newswise — HOUSTON and SOUTH SAN FRANCISCO, Calif. ― The University of Texas MD Anderson Cancer Center and Rigel…
Read More » -
Health News
MD Anderson’s Katy Rezvani, M.D., receives 2023 Honorific Award from the American Society of Hematology
[ad_1] Newswise — Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas…
Read More » -
Health News
Eating beans improves gut health, regulates immune and inflammatory processes in colorectal cancer survivors
[ad_1] Newswise — HOUSTON ― Incorporating navy beans into the diet of colorectal cancer (CRC) survivors has the potential to…
Read More » -
Health News
New combination improves radiation therapy outcomes in patients with locally advanced and borderline resectable pancreatic cancer
[ad_1] Newswise — First author Cullen Taniguchi, M.D., Ph.D., passed away suddenly before the final publication of this study. A…
Read More » -
Health News
MD Anderson announces Institute for Data Science in Oncology to advance mission to end cancer
[ad_1] Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center today announced the launch of its Institute…
Read More » -
Health News
MD Anderson and Jazz Pharmaceuticals announce five-year collaboration to evaluate zanidatamab in HER2-expressing cancers
[ad_1] Newswise — HOUSTON and DUBLIN ― The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced…
Read More » -
Health News
Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
[ad_1] Newswise — HOUSTON ― A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival…
Read More »
